Author Response: Retina Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.
作者信息
Huber Kim Lien, Steiner Irene, Pollreisz Andreas
机构信息
Medical University of Vienna, Department of Ophthalmology, Vienna, Austria.
Medical University of Vienna, Center for Medical Data Science, Institute of Medical Statistics, Vienna, Austria.
出版信息
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):51. doi: 10.1167/iovs.66.11.51.
Abstract
摘要
相似文献
1
Author Response: Retina Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.作者回复：糖尿病性黄斑水肿患者从阿柏西普转换为法西单抗后的视网膜真实世界转归
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):51. doi: 10.1167/iovs.66.11.51.
2
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.在糖尿病性黄斑水肿的约塞米蒂/莱茵试验中，法西单抗与阿柏西普的解剖学对照
Ophthalmol Retina. 2025 Jul;9(7):655-666. doi: 10.1016/j.oret.2025.01.017. Epub 2025 Feb 4.
3
Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.从阿柏西普转换为 faricimab 治疗抵抗性新生血管年龄相关性黄斑变性的结局。
Ophthalmol Retina. 2024 Jun;8(6):537-544. doi: 10.1016/j.oret.2023.11.015. Epub 2023 Nov 29.
4
Comments on "Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema".关于“糖尿病性黄斑水肿患者从阿柏西普转换为法西单抗后的真实世界转归”的评论
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):52. doi: 10.1167/iovs.66.11.52.
5
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.在3期约塞米蒂和莱茵试验中，法西单抗与阿柏西普对糖尿病性黄斑水肿患者2年内视网膜前膜形成的影响
Retina. 2025 Jul 14. doi: 10.1097/IAE.0000000000004572.
6
Six-month comparative outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion.阿柏西普和法西单抗治疗初治的视网膜分支静脉阻塞继发黄斑水肿的6个月比较结果。
Jpn J Ophthalmol. 2025 Jul 22. doi: 10.1007/s10384-025-01254-8.
7
Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study).法西单抗治疗脉络膜视网膜疾病的真实世界研究结果：印度真实世界分析（FOCUS研究）
Clin Ophthalmol. 2025 Jun 12;19:1855-1862. doi: 10.2147/OPTH.S521384. eCollection 2025.
8
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.患有糖尿病性黄斑水肿且视力<20/40 的眼睛转为使用阿柏西普时符合转换标准的风险因素。
Ophthalmology. 2024 Aug;131(8):967-974. doi: 10.1016/j.ophtha.2024.01.037. Epub 2024 Feb 8.
9
Initial Response After Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration.转换为阿柏西普8毫克治疗新生血管性年龄相关性黄斑变性后的初始反应
J Clin Med. 2025 Jul 8;14(14):4824. doi: 10.3390/jcm14144824.
10
Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.在先前接受抗血管内皮生长因子治疗后转为使用法西单抗治疗持续性糖尿病黄斑水肿：一项系统评价和荟萃分析
Graefes Arch Clin Exp Ophthalmol. 2025 Jun 27. doi: 10.1007/s00417-025-06878-7.
本文引用的文献
1
Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.糖尿病性黄斑水肿患者从阿柏西普转换为法西单抗后的真实世界转归
Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):46. doi: 10.1167/iovs.65.14.46.
2
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.《流行病学观察性研究报告强化（STROBE）声明》：观察性研究报告指南
Ann Intern Med. 2007 Oct 16;147(8):573-7. doi: 10.7326/0003-4819-147-8-200710160-00010.
Zotero 插件